AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury AM-Pharma B.

Related StoriesAlport syndrome: an interview with Dr Paul Grint, CMO, RegulusDiabetic retinopathy therapy improvements: an interview with Richard Kirk, CEO of PolyphotonixElectronic cigarettes and smoking cigarettes cessation: an interview with Professor Peter Hajek The trial also founded recAP's pharmacokinetic properties. Included in these are dosage exposures up to and above the mark therapeutic range as established in AM-Pharma's earlier positive Phase II clinical trial results with bovine Alkaline Phosphatase , in the treating patients with Acute Kidney Damage . Our prosperity of knowledge around Alkaline Phosphatase, obtained from our earlier Stage II programmes with bovine AP, meant that at the start of this clinical trial we expected that recAP would be safe and well tolerated, stated Erik van den Berg, CEO of AM-Pharma.Based on the Consumer Product Basic safety Commission, little magnets can kill kids if two or more are swallowed, because they are able to attract to one another through the intestinal wall space. This traps the magnets set up and can cause holes, twisting and/or blockage of the intestines, infection, and potentially fatal blood poisoning referred to as sepsis. Surgery is usually necessary to remove the magnets, and sometimes parts of the intestines have to be removed.There have already been 22 cases of children swallowing magnets since 2009. Relating to CPSC, it is very hard for parents to notice if a magnet or two are lacking from a set, which could consist of up to 200 tiny magnets. Parents may see symptoms like abdominal pains, nausea, vomiting and diarrhea.